Noster

Noster is a Japanese biotechnology company specializing in the research and development of gut microbiota-derived metabolites, specifically postbiotics. Spun off from Nitto Pharmaceutical Industries, the company focuses on the therapeutic potential of fatty acid metabolites produced by gut bacteria to treat metabolic and inflammatory diseases. Their lead research involves 10-hydroxy-cis-12-octadecenoic acid (HYA), which targets G protein-coupled receptors to regulate glucose metabolism and inflammation. Noster provides comprehensive gut microbiota analysis services and maintains a large library of intestinal bacterial strains and metabolites. The company aims to develop innovative pharmaceuticals and functional foods based on the symbiotic relationship between humans and their microbiome.